Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Benzinga · 3d ago
Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.